Parth A. Desai, MBBS, MD, was first author on a study that detailed significant findings in small cell lung cancer.

Serious questions must be asked about the current state of interventional trials in the oncology sphere and how to improve their future value.

Cindy M. Pabon, MD, highlights key findings and the clinical implications of 3 trials addressing questions in gastric and gastroesophageal cancer.

Hope S. Rugo, MD, discusses questions regarding CDK4/6 inhibitors and targeted therapies in HR-positive, HER2-negative advanced breast cancer.

Lubna Naaz Chaudhary, MD, MS, highlights the PARSIFAL and Young-PEARL trials and discusses ongoing research in ER-positive/HER2-negative breast cancer.

Nurse-executive and partnership manager honored for dedication to local heroes.

Subcutaneous pembrolizumab plus chemotherapy generated noninferior PK outcomes vs IV pembrolizumab plus chemotherapy in metastatic NSCLC.

The FDA granted fast track designation to ALE.P02 for CLDN1-positive squamous solid tumors.

Nogapendekin alfa inbakicept plus BCG continued to generate complete responses in BCG-unresponsive non–muscle-invasive bladder cancer.

Rasha Cosman, BSc, MBBS, FRACP, and Charlotte Lemech, MBBS, discuss the phase 1 MYE Symphony study (NCT05969041) of MT-302 in advanced or metastatic epithelial cancers.

Second-line BTK inhibitors were associated with improved PFS2 and OS2 in late-relapsed mantle cell lymphoma.

Tanios S. Bekaii-Saab, MD, discusses the role of liquid biopsies and ctDNA in gastrointestinal cancers.

Dr Harrington discusses PDS0101 plus pembrolizumab in HPV16+ HNSCC and how the VERSATILE-003 trial may change the HNSCC treatment paradigm.

Induction therapy with bendamustine plus obinutuzumab resulted in higher CR rates compared with historical rates of CR with BR in treatment-naive MCL.

Lubna Naaz Chaudhary, MD, MS, discusses selecting a CDK4/6 inhibitor in hormone receptor–positive breast cancer.

The UK MHRA approved frontline toripalimab plus chemotherapy for recurrent/metastatic NPC, as well as for advanced, recurrent, or metastatic ESCC.

Investigators are opening a trial to evaluate a novel type of immune cellular therapy in patients with recurrent, platinum-resistant ovarian cancer.

The FDA approved the FoundationOne Liquid CDx to identify patients with mNSCLC with MET exon 14 skipping alterations who may be eligible for tepotinib.

The European Commission has approved mirvetuximab soravtansine for select patients with pretreated FRα-positive, platinum-resistant ovarian cancer.

The EMA’s CHMP has issued a positive opinion regarding the use of amivantamab plus lazertinib in select patients with EGFR+ non–small cell lung cancer.

Experts discuss the ongoing investigation of Versamune HPV plus pembrolizumab and its potential effect on outcomes in first-line HPV16-driven HNSCC.

Cindy M. Pabon, MD, discusses efforts to improve patient outcomes in gastric/GEJ cancer through the development of effective biomarker–targeted therapies.

Tanios S. Bekaii-Saab, MD, discusses the evolution of frontline treatment in advanced pancreatic cancer.

New datopotamab deruxtecan BLA in NSCLC filed to FDA, radiopharmaceutical meets rPFS end point in PSMA+ prostate cancer, and more.

David H. Aggen, MD, PhD, details the evolving landscape of treating patients with urothelial carcinoma.